Abstract
Cancer is currently responsible for approximately one quarter of all deaths each year in the United States [1]. Decades of refinement to cancer treatment has led to a multimodal approach, which combines surgery with radiation and/or chemotherapy. However, aggressive and advanced stages of cancer are only slightly hindered with drugs and radiation at the cost of considerable patient morbidity. Implementation of nanotechnology can increase the potency and decrease the side effects of chemotherapeutic agents by specifically targeting cancerous tissue. Most nanotechnologies available in the clinical market are nanoparticle (NP) based drug delivery vehicles, which attests to the promise for cancer chemotherapy applications. There is a constantly growing list of materials and synthetic techniques that allow for the creation of NPs with different compositions, sizes, charge, architecture, biodegradability and surface moieties, all of which can be adjusted within each class of particle. Ultimately this design freedom can be utilized to take advantage of cancer pathophysiology and specifically target cancerous tissue. When synthesized to a certain size, NPs delivered systemically can exploit the leaky vasculature of cancerous tumors and passively target the desired cancerous tissue. More precision may be gained by attaching ligands that actively target surface moieties that are expressed to a greater extent by cancer. This review summarizes the progress made in the past 5 years in NP chemotherapeutic delivery with a focus on unique applications of passive, active and external targeting strategies followed by a discussion on what strategy is optimal for cancer chemotherapy.
Keywords: Cancer, chemotherapy, nanotechnology, nanoparticles, drug delivery, passive targeting, enhanced permeability and retention effect, active targeting, xenograft tumor model
Current Bioactive Compounds
Title: Recent Developments in Nanoparticle Based Targeted Delivery of Chemotherapeutics
Volume: 5 Issue: 3
Author(s): M. Sean Peach, Sangamesh G. Kumbar, Justin L. Brown and Cato T. Laurencin
Affiliation:
Keywords: Cancer, chemotherapy, nanotechnology, nanoparticles, drug delivery, passive targeting, enhanced permeability and retention effect, active targeting, xenograft tumor model
Abstract: Cancer is currently responsible for approximately one quarter of all deaths each year in the United States [1]. Decades of refinement to cancer treatment has led to a multimodal approach, which combines surgery with radiation and/or chemotherapy. However, aggressive and advanced stages of cancer are only slightly hindered with drugs and radiation at the cost of considerable patient morbidity. Implementation of nanotechnology can increase the potency and decrease the side effects of chemotherapeutic agents by specifically targeting cancerous tissue. Most nanotechnologies available in the clinical market are nanoparticle (NP) based drug delivery vehicles, which attests to the promise for cancer chemotherapy applications. There is a constantly growing list of materials and synthetic techniques that allow for the creation of NPs with different compositions, sizes, charge, architecture, biodegradability and surface moieties, all of which can be adjusted within each class of particle. Ultimately this design freedom can be utilized to take advantage of cancer pathophysiology and specifically target cancerous tissue. When synthesized to a certain size, NPs delivered systemically can exploit the leaky vasculature of cancerous tumors and passively target the desired cancerous tissue. More precision may be gained by attaching ligands that actively target surface moieties that are expressed to a greater extent by cancer. This review summarizes the progress made in the past 5 years in NP chemotherapeutic delivery with a focus on unique applications of passive, active and external targeting strategies followed by a discussion on what strategy is optimal for cancer chemotherapy.
Export Options
About this article
Cite this article as:
Peach Sean M., Kumbar G. Sangamesh, Brown L. Justin and Laurencin T. Cato, Recent Developments in Nanoparticle Based Targeted Delivery of Chemotherapeutics, Current Bioactive Compounds 2009; 5 (3) . https://dx.doi.org/10.2174/157340709789054759
DOI https://dx.doi.org/10.2174/157340709789054759 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Remediation of Cellular Hypoxic Damage by Pharmacological Agents
Current Pharmaceutical Design HGF as Angiogenic Factor and Therapeutic Approach
Current Signal Transduction Therapy Lipid Rafts and Redox Regulation of Cellular Signaling in Cholesterol Induced Atherosclerosis
Current Cardiology Reviews Matrix Metalloproteinase Knockout Studies and the Potential Use of Matrix Metalloproteinase Inhibitors in the Rheumatic Diseases
Current Drug Targets - Inflammation & Allergy Inotropic and Vasoactive Drugs in Pediatric ICU
Current Drug Targets Mesenchymal Stem Cell Therapy for Acetaminophen-related Liver Injury: A Systematic Review and Meta-analysis of Experimental Studies <i>In Vivo</i>
Current Stem Cell Research & Therapy Emerging Roles of Meis1 in Cardiac Regeneration, Stem Cells and Cancer
Current Drug Targets Mechanisms Involved in Apoptosis Events Contributing to Sepsis-Induced Myocardial Dysfunction
Current Drug Therapy Improving Nutritional Quality of Plant Proteins Through Genetic Engineering
Current Genomics Stem Cell Transplantation in Pediatric Leukemia and Myelodysplasia: State of the Art and Current Challenges
Current Stem Cell Research & Therapy Cardiac Effects of HDL and Its Components on Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets MicroRNA-208a Potentiates Angiotensin II-triggered Cardiac Myoblasts Apoptosis via Inhibiting Nemo-like Kinase (NLK)
Current Pharmaceutical Design Erythropoietin: New Horizon in Cardiovascular Medicine
Recent Patents on Cardiovascular Drug Discovery Chromatin Remodeling, DNA Damage Repair and Aging
Current Genomics Co-formulation of P-glycoprotein Substrate and Inhibitor in Nanocarriers: An Emerging Strategy for Cancer Chemotherapy
Current Cancer Drug Targets Recent Patents on Epilepsy Genetics
Recent Patents on DNA & Gene Sequences Targeting Sarcomas: Novel Biological Agents and Future Perspectives
Current Drug Targets Current Status of Therapeutic Angiogenesis with Protein, Gene and Cell Therapy
Current Drug Therapy Molecular Determinants of the Cardiometabolic Phenotype
Endocrine, Metabolic & Immune Disorders - Drug Targets Impact of Pulmonary Vascular Resistances in Heart Transplantation for Congenital Heart Disease
Current Cardiology Reviews